Cargando…

Anti-TNF Withdrawal in Inflammatory Bowel Disease

The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torres, Joana, Cravo, Marília, Colombel, Jean-Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Karger Publishers 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580146/ https://www.ncbi.nlm.nih.gov/pubmed/28868451 http://dx.doi.org/10.1016/j.jpge.2015.11.004

Ejemplares similares

New Trends in Inflammatory Bowel Disease
por: Palmela, Carolina, et al.
Publicado: (2015)

The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review
por: Axelrad, Jordan E., et al.
Publicado: (2021)

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
por: Aardoom, Martine A., et al.
Publicado: (2019)

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases
por: Torres, Joana, et al.
Publicado: (2016)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

Conjugal inflammatory bowel disease: a systematic review and European survey
por: Costa-Santos, Maria Pia, et al.
Publicado: (2021)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
por: Wellens, Judith, et al.
Publicado: (2022)

Inflammatory Bowel Disease Patients' Perspectives during COVID-19 Pandemic: Results from a Portuguese Survey
por: Revés, Joana Branco, et al.
Publicado: (2021)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
por: Colombel, Jean-Frédéric, et al.
Publicado: (2020)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

Potential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease
por: Andersen, Vibeke, et al.
Publicado: (2017)

Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy
por: Dahmus, Jessica, et al.
Publicado: (2020)

Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers
por: Cui, Guanglin, et al.
Publicado: (2021)

Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review
por: Mihai, Ioana Ruxandra, et al.
Publicado: (2023)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases
por: Mahmoud, Remi, et al.
Publicado: (2018)

Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases
por: Bek, S., et al.
Publicado: (2016)

Vitamin C Deficiency in Inflammatory Bowel Disease: The Forgotten Micronutrient
por: Dunleavy, Katie A, et al.
Publicado: (2021)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
por: Altwegg, Romain, et al.
Publicado: (2014)

Pott’s Puffy Tumor in an Inflammatory Bowel Disease Patient on Anti-TNF Therapy
por: Miri, Ahmad, et al.
Publicado: (2021)

COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions
por: Ungaro, Ryan C., et al.
Publicado: (2021)

Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance
por: Mahmoud, Remi, et al.
Publicado: (2019)

Evaluation of ileal Crohn’s disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results
por: Gordic, Sonja, et al.
Publicado: (2020)

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease
por: Louis, Edouard
Publicado: (2020)

Anal Neoplasia in Inflammatory Bowel Disease Is Associated With HPV and Perianal Disease
por: Ruel, Joannie, et al.
Publicado: (2016)

Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis
por: Guberna, Laura, et al.
Publicado: (2021)

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
por: Brenner, Erica J., et al.
Publicado: (2020)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2020)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses
por: Agrawal, Manasi, et al.
Publicado: (2021)

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease
por: Okuyucu, Muhammed, et al.
Publicado: (2022)

Familial and ethnic risk in inflammatory bowel disease
por: Santos, Maria Pia Costa, et al.
Publicado: (2018)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
por: Marquez-Megias, Silvia, et al.
Publicado: (2022)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease
por: Parekh, Rajen, et al.
Publicado: (2021)

Unmet needs in inflammatory bowel disease
por: Revés, Joana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hvcm8k59luqn9diccqnur8vk45